16,089 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Bought by Aquatic Capital Management LLC

Aquatic Capital Management LLC bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,089 shares of the specialty pharmaceutical company's stock, valued at approximately $461,000.

Several other institutional investors have also recently added to or reduced their stakes in COLL. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter worth approximately $40,000. KBC Group NV raised its stake in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after acquiring an additional 982 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock valued at $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in Collegium Pharmaceutical in the fourth quarter valued at $230,000.

Insiders Place Their Bets

In related news, CFO Colleen Tupper sold 10,445 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares of the company's stock, valued at $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,693 shares of company stock worth $2,334,994. Company insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ COLL traded down $0.75 during mid-day trading on Tuesday, hitting $27.03. 293,366 shares of the company were exchanged, compared to its average volume of 440,985. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a market cap of $868.53 million, a price-to-earnings ratio of 11.65 and a beta of 0.63. The stock has a 50 day simple moving average of $28.18 and a 200-day simple moving average of $30.23. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on COLL shares. Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. Needham & Company LLC restated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.